Nanotechnology and Drug Delivery basic research focuses on designing new drugs that cross multiple biological barriers to block gliomas growth.
Immunotherapy is one of the fastest developing approaches in clinical oncology and has provided successful treatment of different cancers. However, the unique immune environment of the central nervous system needs consideration when pursuing immunotherapeutic approaches for gliomas. Treatment options are limited, in part, due to inefficient drug delivery across the blood-brain barrier (BBB). Therefore, new nano immunoconjugates based on natural biopolymer scaffold, poly(b-L-malic acid), with covalently attached a-CTLA-4 and/or a-PD-1 for delivery across the BBB and activation of local brain anti-tumor immune response, were developed.
Noninvasive imaging agents to precisely diagnose different brain pathological conditions are under constant development for selective targeting and treatment of brain metastasis from primary tumors originating in the lung, breast and other organs.
The aim of the Nanotechnology and Drug Delivery research team is to create a new generation of drugs with the ability to:
- Improve the pharmaceutical and pharmacological properties of anti-cancer drugs
- Increase the therapeutic efficacy of drug delivery
- Deliver multiple types of therapeutics for combination therapy of cancer and neurodegenerative disorders, such as anti-Alzheimer's diagnostic and therapeutic nanodrugs